Oct 2010/AASLD: Present complete datasets from IDX184, IDX320, and IDX375 studies for which top-line data was reported in IDIX’s 9/7/10 PR (#msg-54120531).
Late 2010/early 2011: Possible lifting of clinical hold on IDX184 and/or IDX320 programs following FDA review of combination animal-tox study and all clinical data to date.
Late 2010: Select lead NS5A compound. Start phase-1 trial in 1H11.
HIV
4Q10: GSK enrolls first patient in phase-2b SONNET trial, which will generate a significant milestone payment for IDIX from GSK (#msg-55627169, #msg-49743057).
Early 2011: GSK start IDX899 phase-2b trial in first-line setting, testing IDX899+Truvada vs Sustiva+Truvada.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.